Entasis Therapeutics Holdings Inc.

Entasis reported a net loss of $12 million for the three months ended June 30, 2021, versus a net loss of $13.4 million in the prior-year period. Research and development expense was $10 million, compared with $10.2 million a year ago, and general and administrative expense was $3.3 million versus $3.2 million. Cash and cash equivalents were $56.4 million at June 30, 2021, up from $53.2 million at December 31, 2020. The company also completed a private placement that provided net proceeds of approximately $20 million. Management said existing cash, including the new financing, should fund operating expenses through the second quarter of 2022. Forward-looking guidance included top-line ATTACK data early in the fourth quarter, a post-data FDA discussion, and eventual NDA filing and launch readiness for SUL-DUR; no completion guidance was given for the Zoliflodacin trial.

Manoussos Perros framed the quarter as a transition toward commercialization, emphasizing that ATTACK enrollment is complete and that top-line data is imminent. He said the company is already preparing for commercialization planning and NDA-related steps, but stressed that launch strategy will depend on the Phase 3 data. His tone was confident but measured, with repeated emphasis on the significance of the upcoming readout and the need to wait for the full dataset.

Mike Gutch said the company improved its balance sheet with about $20 million in net proceeds from a private placement with Innoviva, and that the funds will support completion of ATTACK, NDA filing preparation, SUL-DUR launch readiness, working capital, and general corporate purposes. He reported cash and cash equivalents of $56.4 million as of June 30, 2021, and said that, together with the new financing, this should fund operations through the second quarter of 2022. He also noted the quarterly net loss of $12 million, with R&D at $10 million and G&A at $3.3 million.

Analysts focused heavily on ATTACK readout details, asking which secondary endpoints would be highlighted, what the regulatory path would look like after top-line data, and what the company is doing for pre-commercial launch preparation. Management said the top-line package will include 28-day all-cause mortality, nephrotoxicity by RIFLE, 14-day mortality, clinical outcomes, demographics, infection types, and safety comparisons, while the next major step after data is full analysis followed by a meeting with the FDA, ideally a pre-NDA meeting. On Part B of ATTACK, management said its data will be part of the application as descriptive/supportive efficacy and part of the overall safety database, though not the primary efficacy analysis. For Zoliflodacin, management said enrollment remains challenged by COVID-19 and they are trying to mitigate delays by improving enrollment at existing sites, opening new sites, and potentially expanding into other geographies.